Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer

被引:25
|
作者
Ji, Huihui [1 ]
Zhang, Jian-an [1 ]
Liu, Hejing [1 ]
Li, Kehan [1 ]
Wang, Zhi-wei [1 ]
Zhu, Xueqiong [1 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 2, Ctr Uterine Canc Diag & Therapy Res Zhejiang Prov, Dept Obstet & Gynecol, Wenzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
cervical cancer; M6A; TME; PD-1; PD-L1; TIME; MESSENGER-RNA; CELLS;
D O I
10.3389/fimmu.2022.976107
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Understanding the role of N6-adenosine methylation (m6A) in the tumor microenvironment (TME) is important since it can contribute to tumor development. However, the research investigating the association between m6A and TME and cervical cancer is still in its early stages. The aim of this study was to discover the possible relationship between m6A RNA methylation regulators, TME, PD-L1 expression levels, and immune infiltration in cervical cancer. We gathered RNA-seq transcriptome data and clinical information from cervical cancer patients using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. To begin, researchers assessed the differences in m6A regulatory factor expression levels between cervical cancer and normal tissues. Clustering analysis was adapted to assess PD-L1 expression, immunological score, immune cell infiltration, TME, and probable pathways in cervical cancer samples. The majority of m6A regulators were found to be considerably overexpressed in cervical cancer tissues. Using consensus clustering of 21 m6A regulators, we identified two subtypes (clusters 1/2) of cervical cancer, and we found that WHO stage and grade were associated with the subtypes. PD-L1 expression increased dramatically in cervical cancer tissues and was significantly linked to ALKBH5, FTO, METTL3, RBM15B, YTHDF1, YTHDF3, and ZC3H13 expression levels. Plasma cells and regulatory T cells (Tregs) were considerably elevated in cluster 2. Cluster 1 is involved in numerous signature pathways, including basal transcription factors, cell cycle, RNA degradation, and the spliceosome. The prognostic signature-based riskscore (METTL16, YTHDF1, and ZC3H13) was found to be an independent prognostic indicator of cervical cancer. The tumor immune microenvironment (TIME) was linked to m6A methylation regulators, and changes in their copy number will affect the quantity of tumor-infiltrating immune cells dynamically. Overall, our research discovered a powerful predictive signature based on m6A RNA methylation regulators. This signature correctly predicted the prognosis of cervical cancer patients. The m6A methylation regulator could be a critical mediator of PD-L1 expression and immune cell infiltration, and it could have a significant impact on the TIME of cervical cancer.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer
    Chong, Wei
    Shang, Liang
    Liu, Jin
    Fang, Zhen
    Du, Fengying
    Wu, Hao
    Liu, Yang
    Wang, Zhe
    Chen, Yang
    Jia, Shengtao
    Chen, Liming
    Li, Leping
    Chen, Hao
    THERANOSTICS, 2021, 11 (05): : 2201 - 2217
  • [32] The Tumor Microenvironment Mediates the HIF-1α/PD-L1 Pathway to Promote Immune Escape in Colorectal Cancer
    Sun, Jing
    Zhao, Zhengtian
    Lu, Jiaqi
    An, Wen
    Zhang, Yiming
    Li, Wei
    Yang, Li
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [33] Comprehensive landscape of m6A regulator-related gene patterns and tumor microenvironment infiltration characterization in gastric cancer
    Peng, Bin
    Lin, Yinglin
    Yi, Gao
    Lin, Mingzhen
    Xiao, Yao
    Qiu, Yezhenghong
    Yao, Wenxia
    Zhou, Xinke
    Liu, Zhaoyu
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [34] Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review
    Wang, Nuo-Han
    Lei, Zheng
    Yang, Hao-Nan
    Tang, Zheng
    Yang, Meng-Qi
    Wang, Ying
    Sui, Jiang-Dong
    Wu, Yong-Zhong
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (24)
  • [35] Comparative evaluation of PD-L1 expression and tumor immune microenvironment in molecular subtypes of muscle-invasive bladder cancer and its correlation with survival outcomes
    Khandakar, Hena
    Kaushal, Seema
    Seth, Amlesh
    Sahoo, Ranjit K.
    Narwal, Anubhav
    Jangir, Hemlata
    Nayak, Brusabhanu
    Dinda, Amit K.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2025,
  • [36] Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
    He, Jiabei
    Hu, Ying
    Hu, Mingming
    Li, Baolan
    SCIENTIFIC REPORTS, 2015, 5
  • [37] M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
    Qiu, Xinyao
    Yang, Shuai
    Wang, Shan
    Wu, Jianmin
    Zheng, Bo
    Wang, Kaiting
    Shen, Siyun
    Jeong, Seogsong
    Li, Zhixuan
    Zhu, Yanjing
    Wu, Tong
    Wu, Xuan
    Wu, Rui
    Liu, Weiwei
    Wang, Hong-Yang
    Chen, Lei
    CANCER RESEARCH, 2021, 81 (18) : 4778 - 4793
  • [38] LINC00861 Promotes Immune Response in the Tumor Microenvironment and Inhibits Prostate Cancer Tumor Growth by Regulating PD-L1
    Lu, Xiaojun
    Ma, Quan
    Gao, Wenwen
    Zhou, Tie
    Hou, Jianquan
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2024, 38 (01) : 467 - 478
  • [39] m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Cell-Infiltration Characterization in Head and Neck Cancer
    Yang, Qinghui
    Xu, Feng
    Jian, Aiwen
    Yu, Hongmei
    Ye, Tao
    Hu, Weiqi
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 9
  • [40] N6-Methyladenosine (m6A) Reader IGF2BP1 Accelerates Gastric Cancer Development and Immune Escape by Targeting PD-L1
    Tang, Bingxi
    Bi, Lei
    Xu, Yanbin
    Cao, Lili
    Li, Xinli
    MOLECULAR BIOTECHNOLOGY, 2024, 66 (10) : 2850 - 2859